Elsevier

Respiratory Medicine

Volume 85, Issue 2, March 1991, Pages 139-145
Respiratory Medicine

Inflammatory markers in cystic fibrosis

https://doi.org/10.1016/S0954-6111(06)80292-1Get rights and content

Plasma neutrophil elastase-a1 antiproteinase complex, lactoferrin and C-reactive protein (CRP) were determined over a 15-month period in 26 patients with cystic fibrosis, of whom 21 were chronically infected with Pseudomonas aeruginosa. Median concentrations of both neutrophil products and CRP were greater in patients who were clinically stable than in healthy subjects without cystic fibrosis. CRP concentrations increased further at the onset of symptomatic exacerbations. Thirty-five courses of intravenous antibiotics and 22 courses of oral ciprofloxacin were reviewed and revealed similar improvements in clinical scores and lung function tests for both forms of treatment. Intravenous antibiotics reduced the plasma concentrations of both neutrophil products and CRP, while oral ciprofloxacin only significantly reduced the concentration of neutrophil elastase-a1 antiproteinase complex. Plasma concentrations of inflammatory markers were significantly greater in exacerbations associated with fever and leukocytosis. Statistical modelling demonstrated negative within-patient relationships between lung function and both CRP and lactoferrin, and positive relationships between the three inflammatory markers. Neutrophil granule products and CRP reflect the pulmonary inflammatory state in cystic fibrosis and may be of value in monitoring treatment.

References (19)

There are more references available in the full text version of this article.

Cited by (53)

  • C-Reactive Protein Concentration in Steady-State Bronchiectasis: Prognostic Value of Future Severe Exacerbations. Data From the Spanish Registry of Bronchiectasis (RIBRON)

    2021, Archivos de Bronconeumologia
    Citation Excerpt :

    One of the inflammatory biomarkers most extensively studied is C-reactive protein (CRP).21 An increase in the systemic concentration of this molecule has been associated with greater severity of asthma, COPD, and cystic fibrosis (CF).22–27 However, data on the relationship between the concentration of CRP in clinically stable state and BE is still scarce, particularly with respect to the number and severity of exacerbations.28

  • Laboratory biomarkers for lung disease severity and progression in cystic fibrosis

    2020, Clinica Chimica Acta
    Citation Excerpt :

    Reviewed studies with a focus on distinct blood-based biomarkers determined in different patient populations with various clinical utilities are summarized in Table 1. Serum or plasma CRP concentrations as indicators of systemic inflammation in CF have been analyzed since the early nineties of the last century when these were first found to be increased in CF [41]. After a 2 week-intravenous ciprofloxacin administration, serum CRP was significantly reduced compared to pre-treatment values in CF demonstrating its utility in monitoring treatment efficiency as well [41].

  • RNA sequencing data from neutrophils of patients with cystic fibrosis reveals potential for developing biomarkers for pulmonary exacerbations

    2019, Journal of Cystic Fibrosis
    Citation Excerpt :

    Systemic monitoring of inflammation via blood sampling is ideal because it has the potential to reflect the status of inflammation throughout the entire lung, and blood is relatively simple to obtain from patients of all ages. Blood-based biomarkers have been studied in CFPE for nearly 3 decades, and have included acute phase reactants, markers of oxidative stress, neutrophil elastase 1-antiprotease complexes [7], lactoferrin [8, 9], calprotectin [10] and other products of inflammation [11]. The gene expression profile of neutrophils has been recently studied in CF by using hybridization-based microarrays [12].

  • Systematic review of blood biomarkers in cystic fibrosis pulmonary exacerbations

    2013, Chest
    Citation Excerpt :

    The use of CRP as a biomarker of CFPE onset was investigated in nine studies, and a statistical analysis was conducted in six of these. Five of the six studies demonstrated a statistically significant increase in CRP levels from the stable to the CFPE state.14,32,33,52,53 Based on a quantitative review of the average and the variability in CRP levels among health states for each study, the average increase appeared to be large, but there was also substantial variation in the average measurements within each health state (e-Table 4).

  • Mucoid Pseudomonas aeruginosa caused by mucA mutations result in activation of TLR2 in addition to TLR5 in airway epithelial cells

    2012, Biochemical and Biophysical Research Communications
    Citation Excerpt :

    Therefore signals that increase inflammation in chronically infected CF patients may worsen decline in lung function. Markers of inflammation are increased at the onset of pulmonary exacerbations [3] and following these episodes, a net decline in lung function has been documented from pre-exacerbation state [21]. Unfortunately, very little is known about pulmonary exacerbations.

View all citing articles on Scopus
View full text